Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
ZyVersa Therapeutics, Inc. (ZVSA) had Consolidated Net Income/Loss of $-2.21M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-2.21M |
|
-- |
|
-- |
|
$2.04M |
|
$-2.04M |
|
$-0.17M |
|
$-2.21M |
|
$-2.21M |
|
$-2.21M |
|
$-2.21M |
|
|
Consolidated Net Income/Loss |
$-2.21M |
$-2.21M |
|
$-2.04M |
|
$-2.04M |
|
4.81M |
|
4.81M |
|
$-0.46 |
|
$-0.46 |
|
| Balance Sheet Financials | |
$0.55M |
|
-- |
|
$19.09M |
|
$19.64M |
|
$12.69M |
|
-- |
|
$0.85M |
|
$13.54M |
|
$6.10M |
|
$-12.55M |
|
$6.10M |
|
4.87M |
|
| Cash Flow Statement Financials | |
$-3.29M |
|
-- |
|
$1.83M |
|
$1.53M |
|
$0.07M |
|
$-1.46M |
|
$0.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.04 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.29M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-36.25% |
|
17.62% |
|
-11.26% |
|
-36.25% |
|
$1.25 |
|
$-0.68 |
|
$-0.68 |
|